331830-20-7

1,4-DPCA (331830-20-7) is a potent inhibitor of prolyl 4-hydroxylase (IC50=2-4 μM).1 Inhibits collagen deposition via inhibition of collagen proline hydroxylation.2,3 Subcutaneous injection of a 1,4-DPCA containing hydrogel into Swiss Webster mice that do not show a regenerative phenotype increased expression of HIF1α over 5 days. Multiple injections led to regenerative wound healing after ear hole punch injury.4

1,4-DPCA nis a potent competitive inhibitor of avian prolyl 4-hydroxylase in embryonic chick tendon cells and human foreskin fibroblasts in vitro. It is a promotor of wound healing and tissue regeneration in mice.

[1] T J FRANKLIN. Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones.[J]. Biochemical Journal, 2001, 353 Pt 2: 333-338. DOI:10.1042/0264-6021:3530333
[2] GAOFENG XIONG. Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.[J]. BMC Cancer, 2014: 1. DOI:10.1186/1471-2407-14-1
[3] RYAN J. LOVE  Kim S J. Transient inhibition of connective tissue infiltration and collagen deposition into porous poly(lactic-co-glycolic acid) discs[J]. Journal of biomedical materials research. Part A, 2013, 101 12: 3599-3606. DOI:10.1002/jbm.a.34648
[4] YONG ZHANG. Drug-induced regeneration in adult mice[J]. Science Translational Medicine, 2015, 7 290. DOI:10.1126/scitranslmed.3010228